Zeynep Tuğba Karabulut
Aim: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disorder characterized by complement-mediated intravascular hemolysis, thrombosis, and bone marrow failure.Over the past decade, advances in complement-inhibition therapies have significantly transformed disease management.This study aimed to provide a comprehensive bibliometric and scientometric analysis of global PNH research published between 2015 and 2025 and to identify research trends, thematic evolution, and collaborative networks.Methods: Publications indexed in the Web of Science Core Collection between 2015 and 2025 were retrieved using a topic-based search strategy.After manual screening of records, 1,352 English language articles and reviews were included.VOSviewer and CiteSpace were used to perform collaboration, keyword co-occurrence, and temporal cluster analyses.Results: Annual PNH-related publications generally demonstrated an increasing trend, particularly after 2018, coinciding with the clinical expansion of complement-inhibition strategies.Keyword analysis revealed four principal thematic clusters: (1) complement-mediated hemolysis and therapy; (2) bone marrow failure syndromes; (3) diagnostics and molecular biology; and (4) clinical outcomes and complications.A temporal analysis demonstrated a shift from mechanistic and diagnostic studies (2015)(2016)(2017)(2018) to therapeutic innovation and long-term outcomes research (2022)(2023)(2024)(2025).The United States emerged as the leading contributor and central hub of international collaboration, followed by Japan, England, and Italy.Research activity from Asian countries has increased in recent years.Conclusion: PNH research over the past decade has shifted from foundational disease characterization toward therapeutic optimization and personalized management strategies.Complement inhibition remains the central focus of investigation.Continued international collaboration and research on emerging therapies and real-world outcomes are essential to address unmet clinical needs.